Anthropic runs a wet lab for biological experiments

Anthropic’s wet biology lab in the Bay Area

Anthropic, the AI startup known for its Claude models, now runs a wet biology lab in the San Francisco Bay Area.

The lab enables Anthropic’s large language models to design and execute physical experiments on living cells and molecules.

CEO Dario Amodei recently said, “I believe that AI could cure most major diseases in the next 5–10 years.”

To turn such optimism into reality, the company argues that artificial intelligence must be able to test hypotheses in a real laboratory.

“We believe that to do biology, the final test is still, and will be for a while, in real lab work,” Anthropic’s head of life sciences Eric Kauderer‑Abrams told Reuters.

He added, “We absolutely are doing that today.”

According to Kauderer‑Abrams, the wet lab operates like most biotech facilities, conducting internal research while collaborating with external partners.

Focus on fundamental biology rather than drug discovery

Anthropic’s entry into wet‑lab work was preceded by its April acquisition of Coefficient Bio, a stealth AI‑biotech startup.

The company declined to disclose specific projects, but emphasized that the lab’s primary focus is fundamental biology, not direct drug discovery.

Anthropic wants to avoid the appearance of competing with the pharmaceutical industry, where it already counts major customers and partners.

For example, the firm recently announced a joint drug‑discovery partnership with Novo Nordisk.

Past tensions have arisen when Anthropic launched products that some customers perceived as competitive.

To address such concerns, Anthropic introduced a Life Sciences Verification Program this week, granting vetted bio‑researchers access to its most powerful models.

It has also published reports describing work that could accelerate protein design and uplift bimolecular modeling.

Industry reaction and safety concerns

The announcement of a wet lab has drawn sharp reactions amid ongoing debates about AI safety.

Researcher Jacob Coxon resigned, warning that “the people building AI earnestly believe that it could kill us all by the end of the decade.”

Anthropic’s own alignment lead later estimated greater than a 10 % chance that AI could exterminate humanity within the next decade.

In response, CEO Dario Amodei posted a call for the industry to slow down development and adopt self‑regulation.

He has repeatedly highlighted bioterrorism as one of the greatest risks posed by advanced AI systems.

Investor and AI‑coding startup founder Chamath Palihapitiya reacted on X, writing, “The group behind such hits as: ‘We’re All Going To Die’ and ‘Regulate Me Now’ are building a wet lab in SF. I do not recommend this.”

The juxtaposition of ambitious biological research and dire safety warnings underscores the tension between AI‑driven innovation and existential risk management.

Observers will watch how Anthropic balances its scientific ambitions with the growing demand for responsible AI governance.

Why This Matters: Anthropic’s wet lab shows AI can now directly conduct biological experiments, intensifying both its scientific potential and the urgency of safety oversight.